Recent Clinical Trial Evidence Supporting the Use of Dual GIP/GLP-1 Receptor Agonists

The management of type 2 diabetes has evolved considerably over the past decade, largely driven by the success of incretin-based therapies. Glucagon-like peptide-1 (GLP-1) receptor agonists have become a mainstay for glycemic control and weight reduction, but the emergence of dual agonists that also target the glucose-dependent insulinotropic polypeptide (GIP) receptor represents a significant step forward. Recent large-scale clinical trials have provided robust evidence that dual GIP/GLP-1 receptor agonists not only improve hemoglobin A1c (HbA1c) and body weight more effectively than single GLP-1 receptor agonists but also offer a favorable safety profile and potential cardiovascular benefits. This article reviews the latest clinical trial data supporting the use of dual GIP/GLP-1 receptor agonists, with a focus on tirzepatide and the emerging agent retatrutide, and discusses the implications for diabetes care.

Mechanism of Action: Dual Incretin Stimulation

Dual GIP/GLP-1 receptor agonists, such as tirzepatide, are designed as single molecules that activate both the GIP and GLP-1 receptors. GLP-1 receptor activation enhances glucose-dependent insulin secretion, suppresses inappropriately high glucagon release, slows gastric emptying, and promotes satiety via central nervous system pathways. GIP, previously considered less effective in type 2 diabetes due to reduced insulinotropic action, has been rediscovered as a complementary partner. In the presence of hyperglycemia, GIP also stimulates insulin secretion and may directly improve pancreatic beta-cell function. Moreover, GIP appears to potentiate GLP-1’s anorectic effects and may contribute to favorable energy metabolism through actions on adipose tissue and bone. The synergy between these two incretins results in greater reductions in HbA1c and body weight than either mechanism alone, a hypothesis confirmed in head-to-head trials.

Key Clinical Trial Evidence

Tirzepatide: The SURPASS Program

The most extensive clinical trial program for a dual GIP/GLP-1 receptor agonist is the SURPASS series, which evaluated tirzepatide across several patient populations. The SURPASS-2 trial directly compared tirzepatide (5 mg, 10 mg, and 15 mg) with the potent GLP-1 receptor agonist semaglutide (1 mg) in patients with type 2 diabetes inadequately controlled on metformin. Results published in The Lancet showed that all doses of tirzepatide were superior to semaglutide 1 mg in reducing HbA1c, with mean reductions ranging from 2.0% to 2.3% versus 1.9% for semaglutide. Weight loss was also significantly greater: patients receiving tirzepatide 15 mg lost an average of 11.2 kg compared to 5.4 kg with semaglutide. The SURPASS-1 monotherapy trial confirmed that tirzepatide alone could achieve a placebo-adjusted HbA1c reduction of up to 1.9% and weight loss of up to 7.5 kg.

In the SURPASS-4 trial, tirzepatide was evaluated in patients with type 2 diabetes at high cardiovascular risk, with a composite cardiovascular outcome as a secondary endpoint. This 52-week trial demonstrated that tirzepatide was non-inferior to insulin glargine for major adverse cardiovascular events (MACE-4), with a numeric trend favoring tirzepatide for reducing cardiovascular death, myocardial infarction, and stroke. Importantly, tirzepatide achieved a mean HbA1c reduction of 2.4% compared to 0.9% for insulin glargine, along with 8.5 kg weight loss versus a 1.9 kg gain in the insulin group. The SURPASS program also included dedicated cardiovascular outcome trials (e.g., SURPASS-CVOT) which, at the time of writing, had not been fully reported, but early data suggest a favorable trend.

The SURPASS-AP and SURPASS-J trials extended these findings to East Asian populations, demonstrating consistent efficacy and safety across racial and ethnic groups. Overall, tirzepatide’s efficacy is dose-dependent, with the 10 mg and 15 mg doses providing the largest benefits. The U.S. Food and Drug Administration (FDA) granted approval for tirzepatide (Mounjaro) for type 2 diabetes in May 2022, and it has since become a widely prescribed second- or third-line agent. For more detailed trial results, see the official FDA labeling for tirzepatide (FDA label for Mounjaro).

Retatrutide: A Triple Agonist in Development

Building on the dual-agonist concept, retatrutide (LY3437943) is a novel single molecule that activates GIP, GLP-1, and glucagon receptors. Preliminary data from the Phase 2 trial, presented at the American Diabetes Association Scientific Sessions in 2023, have generated considerable interest. In a 48-week study involving patients with type 2 diabetes, retatrutide (4 mg, 8 mg, or 12 mg weekly) produced profound reductions in HbA1c (up to 2.2% from baseline) and substantial weight loss—up to 17.8 kg (approximately 17% of body weight) at the highest dose. These effects were superior to both placebo and dulaglutide (a GLP-1 receptor agonist). Although retatrutide is not yet approved, these results suggest that triple agonism may achieve even greater metabolic improvements than dual agonism, particularly in weight reduction. Ongoing Phase 3 trials (TRANSCEND-T2D program) will further define its safety and efficacy. For details on retatrutide’s Phase 2 data, see the clinical trial record at ClinicalTrials.gov: NCT04867733.

Safety and Tolerability Across Trials

The safety profile of dual GIP/GLP-1 receptor agonists is largely consistent with that of GLP-1 receptor agonists alone. The most commonly reported adverse events are gastrointestinal: nausea, diarrhea, vomiting, and constipation. These events are dose-dependent and tend to occur early, often diminishing with continued use. In the SURPASS trials, discontinuation rates due to adverse events were approximately 5–10% across tirzepatide arms, comparable to or slightly higher than semaglutide but lower than insulin glargine. Serious adverse events, including pancreatitis and cholecystitis, were rare and balanced between treatment groups. No new safety signals, such as increased risk of medullary thyroid carcinoma or severe hypoglycemia (except when used with sulfonylureas or insulin), have emerged. Retatrutide’s Phase 2 safety data showed a similar gastrointestinal profile, with no unexpected events, although the small sample size limits firm conclusions. Regulatory agencies continue to monitor for longer-term risks, but current evidence supports a favorable benefit-risk profile for dual agonists.

Comparative Efficacy: Dual Agonists vs. Single GLP-1 Receptor Agonists

Head-to-head comparisons between tirzepatide and semaglutide (SUSTAIN and SURPASS-2) consistently demonstrate the superiority of dual agonism. In SURPASS-2, the 10 mg and 15 mg doses of tirzepatide outperformed semaglutide 1 mg in both HbA1c lowering and weight loss. A network meta-analysis of multiple randomized controlled trials published in Diabetes Care confirmed that tirzepatide 15 mg is among the most effective glucose-lowering and weight-reducing agents available for type 2 diabetes. Interestingly, the GIP component appears to mitigate some of the gastrointestinal side effects typically seen with high-dose GLP-1 receptor agonists, possibly by slowing gastric emptying in a more balanced manner. For patients who have suboptimal responses to GLP-1 monotherapy, switching to a dual agonist offers a clear advantage. The American Diabetes Association (ADA) Standards of Care now include tirzepatide as a recommended agent for patients with type 2 diabetes who require additional glucose lowering and weight management (ADA 2023 Pharmacologic Approaches).

Cardiovascular Outcomes and Organ Protection

Although the primary cardiovascular outcome trials for dual agonists are still ongoing (e.g., SURPASS-CVOT), current evidence suggests potential cardiovascular benefits. In SURPASS-4, tirzepatide was non-inferior to insulin glargine for MACE-4, with a hazard ratio of 0.83 (95% CI 0.52–1.33) in the time-to-event analysis, indicating no increased risk. Additionally, tirzepatide significantly reduced systolic blood pressure (by 3–9 mmHg) and improved lipid profiles (reductions in triglycerides, LDL cholesterol, and apolipoprotein B). These effects are likely mediated by weight loss and direct vascular actions. Preclinical studies have shown that dual GIP/GLP-1 activation reduces inflammation and improves endothelial function, independent of glycemic changes. For patients with type 2 diabetes and established atherosclerotic cardiovascular disease, the expected benefits of dual agonists are substantial, although confirmatory data from dedicated cardiovascular outcome trials are eagerly awaited.

Beyond cardiovascular protection, dual agonists have demonstrated positive effects on non-alcoholic fatty liver disease (NAFLD). In a subset analysis of the SURPASS trials, tirzepatide significantly reduced liver fat content and serum alanine aminotransferase levels. Retatrutide’s glucagon activity may further enhance hepatic fat oxidation, making it a promising candidate for metabolic dysfunction-associated steatohepatitis (MASH). These organ-level benefits underscore the potential of dual and triple agonists not only for diabetes but also for obesity and liver disease.

Practical Considerations for Clinical Integration

Incorporating dual GIP/GLP-1 receptor agonists into clinical practice requires attention to several factors. First, these agents are injectable and should be initiated at low doses with gradual titration to minimize gastrointestinal side effects. For tirzepatide, the starting dose is 2.5 mg weekly for four weeks, then titrated to 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg as tolerated. Patients should be counseled that nausea is common but often transient; may be managed by taking injections at bedtime, staying hydrated, and consuming smaller, more frequent meals. Second, dual agonists are costlier than older therapies, though their superior efficacy may offset long-term costs of complications. Many insurance plans now cover tirzepatide for type 2 diabetes, and coverage for obesity (tirzepatide as Zepbound) is expanding. Third, renal and hepatic adjustments are not required for tirzepatide, but caution is warranted in patients with severe gastrointestinal disease (e.g., gastroparesis). Finally, integrating dual agonists with other glucose-lowering agents—particularly metformin, SGLT2 inhibitors, and insulin—should follow established guidelines. The ADA and European Association for the Study of Diabetes (EASD) consensus report now recommends tirzepatide as a high-efficacy option for patients who need substantial reductions in HbA1c and body weight (EASD/ADA Consensus 2022).

Future Directions and Ongoing Research

Several unanswered questions remain. The long-term safety of dual agonists beyond two to three years will be clarified by ongoing extension studies (SURPASS-5, SURPASS-6, and the SURMOUNT obesity trials). The role of dual agonists in type 1 diabetes is being explored, though early data are limited. Additionally, oral formulations of dual agonists are in development; an oral version of tirzepatide (oral semaglutide successor) could broaden patient access. The potential of triple agonists such as retatrutide for obesity and type 2 diabetes is a particularly exciting frontier. If Phase 3 results confirm the extraordinary weight loss observed in Phase 2 (up to 17%), retatrutide may surpass all currently available pharmacotherapies for obesity. Researchers are also investigating dual agonists with once-monthly or even less frequent dosing schedules to improve adherence. Lastly, the combination of dual GIP/GLP-1 receptor agonists with SGLT2 inhibitors is a logical next step, given the complementary mechanisms of action—one targeting the incretin system and the other promoting glucosuria and natriuresis—and early combination data suggest synergistic benefits for glucose, weight, and blood pressure.

Conclusion

Recent clinical trial evidence strongly supports the use of dual GIP/GLP-1 receptor agonists as a powerful advancement in the management of type 2 diabetes and obesity. Tirzepatide has demonstrated superior glycemic control and weight reduction compared to existing GLP-1 receptor agonists, with a safety profile that is manageable and consistent with incretin-based therapy. The emerging triple agonist retatrutide may offer even greater benefits. As cardiovascular outcome data mature and real-world experience accumulates, these agents are likely to become central components of comprehensive diabetes care. Clinicians should familiarize themselves with the dosing, side effect management, and appropriate patient selection to maximize the potential of dual incretin agonism.